Associated tags: Intelligence, Cancer, Therapy, Infection, Clinical trial, DSM-IV codes, Medicine, Drug development, Safety
Locations: WARREN, NJ, US, WALL STREET, UNITED STATES, NORTH AMERICA, NEW JERSEY
Cloud,
Goldman Sachs,
Yale University,
Platform,
Jefferies,
Virology,
Artificial intelligence,
Information technology,
Policy,
Corporate development,
MetLife,
Senior,
Therapy,
Microsoft,
Jefferies Group,
Neurology,
Mobility,
Customer,
CIO,
Bank statement,
Drug discovery,
Biotechnology,
Organization,
Head,
MSIM The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access.
Key Points:
- The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access.
- WARREN, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ) is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
- Second, I’d like to reflect on our recent leadership appointments and the newly launched initiative in Artificial Intelligence (AI).
- Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio.
TVGN,
Cancer,
Cell,
Woman,
MD,
Virology,
Lymphoma,
Therapy,
Neurology,
Virus,
HPV,
EBV,
Clinical trial,
Viral,
Cervical cancer,
Vaccine Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma.
Key Points:
- Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma.
- WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings (Tevogen) ( Nasdaq : TVGN ), is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
- Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer, explains the company’s oncology pipeline strategy.
- Additional approaches are in development to take this approach even further in the treatment of other cancers.”
WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development. Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio.
Key Points:
- WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN ), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development.
- Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio.
- Most recently, Mr. Shah was Director, Relationship Management, in Citigroup’s Client organization, where he was also a member of the Executive Office.
- Prior to Citigroup, he worked in Morgan Stanley’s asset management business (MSIM) focused on Equity Strategy and Product Development.
WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
Key Points:
- WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
- The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.00 conversion price of the Series A Preferred Stock, into a total of 600,000 shares of the Company’s common stock at the election of the holder.
- The Series A-1 Preferred Stock is subject to a call right providing the Company the right to call the stock if the volume weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share and there is an effective resale registration statement on file covering the underlying common stock.
- The Series A-1 Preferred Stock is non-voting, has no mandatory redemption, carries an annual 5% cumulative dividend, increasing by 2% each year, with a cap of 12% per year.
